Adicet Bio, Inc. Operating Expenses
Adicet Bio, Inc. (ACET) reported Operating Expenses of $22.30 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-05
- Adicet Bio, Inc. operating expenses for the quarter ending 2026-06-30 was $22.30M, a 31.15% decline year-over-year.
- Adicet Bio, Inc. operating expenses for the quarter ending 2026-03-31 was $21.57M, a 27.82% decline year-over-year.
- Adicet Bio, Inc. operating expenses for the quarter ending 2025-12-31 was $31.89M, a 3.72% increase year-over-year.
- Adicet Bio, Inc. operating expenses for the quarter ending 2025-09-30 was $27.95M, a 15.69% decline year-over-year.
- Adicet Bio, Inc. operating expenses for fiscal 2025 was $122.11M, a 4.31% decline from fiscal 2024.
- Adicet Bio, Inc. operating expenses for fiscal 2024 was $127.61M, a 16.06% decline from fiscal 2023.
- Adicet Bio, Inc. operating expenses for fiscal 2023 was $152.04M, a 55.87% increase from fiscal 2022.
- Adicet Bio, Inc. operating expenses for fiscal 2022 was $97.54M, a 37.07% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 6 month as first filed | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 12 month | Operating Expenses 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $22.30M 10-Q · filed 2026-08-05 | $43.87M 10-Q · filed 2026-08-05 | $75.76M derived: sum of 3 quarters · filed 2026-08-05 | $103.71M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $21.57M 10-Q · filed 2026-05-13 | $53.46M derived: sum of 2 quarters · filed 2026-05-13 | $81.41M derived: sum of 3 quarters · filed 2026-05-13 | $113.80M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $31.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $59.84M derived: sum of 2 quarters · filed 2026-03-12 | $92.23M derived: sum of 3 quarters · filed 2026-08-05 | $122.11M 10-K · filed 2026-03-12 | ||||
| 2025-09-30 | $27.95M 10-Q · filed 2025-11-05 | $60.34M derived: sum of 2 quarters · filed 2026-08-05 | $90.23M 10-Q · filed 2025-11-05 | $120.97M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $32.39M 10-Q · filed 2026-08-05 | $62.28M 10-Q · filed 2026-08-05 | $93.02M derived: sum of 3 quarters · filed 2026-08-05 | $126.17M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $29.89M 10-Q · filed 2026-05-13 | $60.63M derived: sum of 2 quarters · filed 2026-05-13 | $93.78M derived: sum of 3 quarters · filed 2026-05-13 | $126.63M derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | $30.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $63.90M derived: sum of 2 quarters · filed 2026-03-12 | $96.75M derived: sum of 3 quarters · filed 2026-03-12 | $127.61M 10-K · filed 2026-03-12 | ||||
| 2024-09-30 | $33.15M 10-Q · filed 2025-11-05 | $66.00M derived: sum of 2 quarters · filed 2025-11-05 | $96.87M 10-Q · filed 2025-11-05 | $128.44M derived: sum of 4 quarters · filed 2025-11-05 | ||||
| 2024-06-30 | $32.85M 10-Q · filed 2025-08-07 | $63.72M 10-Q · filed 2025-08-07 | $95.29M derived: sum of 3 quarters · filed 2025-08-07 | $147.55M derived: sum of 4 quarters · filed 2025-08-07 | ||||
| 2024-03-31 | $30.87M 10-Q · filed 2025-05-06 | $62.44M derived: sum of 2 quarters · filed 2025-05-06 | $114.70M derived: sum of 3 quarters · filed 2025-05-06 | $149.59M derived: sum of 4 quarters · filed 2025-05-06 | ||||
| 2023-12-31 | $31.57M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $83.83M derived: sum of 2 quarters · filed 2025-03-06 | $118.72M derived: sum of 3 quarters · filed 2025-03-06 | $152.04M 10-K · filed 2025-03-06 | ||||
| 2023-09-30 | $52.26M 10-Q · filed 2024-11-06 | $87.15M derived: sum of 2 quarters · filed 2024-11-06 | $120.47M 10-Q · filed 2024-11-06 | $152.04M derived: sum of 4 quarters · filed 2024-11-06 | ||||
| 2023-06-30 | $34.89M 10-Q · filed 2024-08-13 | $68.21M 10-Q · filed 2024-08-13 | $99.78M derived: sum of 3 quarters · filed 2024-08-13 | $122.76M derived: sum of 4 quarters · filed 2024-08-13 | ||||
| 2023-03-31 | $33.32M 10-Q · filed 2024-05-14 | $64.89M derived: sum of 2 quarters · filed 2024-05-14 | $87.87M derived: sum of 3 quarters · filed 2024-05-14 | $110.58M derived: sum of 4 quarters · filed 2024-05-14 | ||||
| 2022-12-31 | $31.57M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $54.55M derived: sum of 2 quarters · filed 2024-03-19 | $77.26M derived: sum of 3 quarters · filed 2024-03-19 | $97.54M 10-K · filed 2024-03-19 | ||||
| 2022-09-30 | $22.98M 10-Q · filed 2023-11-08 | $45.69M derived: sum of 2 quarters · filed 2023-11-08 | $65.98M 10-Q · filed 2023-11-08 | $86.99M derived: sum of 4 quarters · filed 2023-11-08 | ||||
| 2022-06-30 | $22.71M 10-Q · filed 2023-08-09 | $42.99M 10-Q · filed 2023-08-09 | $64.00M derived: sum of 3 quarters · filed 2023-08-09 | $81.14M derived: sum of 4 quarters · filed 2023-08-09 | ||||
| 2022-03-31 | $20.28M 10-Q · filed 2023-05-09 | $41.29M derived: sum of 2 quarters · filed 2023-05-09 | $58.43M derived: sum of 3 quarters · filed 2023-05-09 | $74.07M derived: sum of 4 quarters · filed 2023-05-09 | ||||
| 2021-12-31 | $21.01M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $38.15M derived: sum of 2 quarters · filed 2023-03-15 | $53.79M derived: sum of 3 quarters · filed 2023-03-15 | $71.16M 10-K · filed 2023-03-15 | ||||
| 2021-09-30 | $17.14M 10-Q · filed 2022-11-08 | $32.78M derived: sum of 2 quarters · filed 2022-11-08 | $50.15M 10-Q · filed 2022-11-08 | $64.91M derived: sum of 4 quarters · filed 2022-11-08 | ||||
| 2021-06-30 | $15.64M 10-Q · filed 2022-08-10 | $33.01M 10-Q · filed 2022-08-10 | $47.77M derived: sum of 3 quarters · filed 2022-08-10 | $64.46M derived: sum of 4 quarters · filed 2022-08-10 | ||||
| 2021-03-31 | $17.37M 10-Q · filed 2022-05-12 | $32.13M derived: sum of 2 quarters · filed 2022-05-12 | $48.81M derived: sum of 3 quarters · filed 2022-05-12 | $64.91M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | $14.76M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $31.44M derived: sum of 2 quarters · filed 2022-03-15 | $47.54M derived: sum of 3 quarters · filed 2022-03-15 | $57.09M 10-K · filed 2022-03-15 | ||||
| 2020-09-30 | $16.68M 10-Q · filed 2021-11-10 | $32.78M derived: sum of 2 quarters · filed 2021-11-10 | $42.34M 10-Q · filed 2021-11-10 | $51.48M derived: sum of 4 quarters · filed 2021-11-10 | ||||
| 2020-06-30 | $16.09M 10-Q · filed 2021-08-12 | $5.65M 10-Q · filed 2020-07-30 | $25.65M 10-Q · filed 2021-08-12 | $13.03M 10-Q · filed 2020-07-30 | $34.80M derived: sum of 3 quarters · filed 2021-08-12 | $42.98M derived: sum of 4 quarters · filed 2021-08-12 | ||
| 2020-03-31 | $9.56M 10-Q · filed 2021-05-17 | $7.38M 10-Q · filed 2020-05-07 | $18.70M derived: sum of 2 quarters · filed 2021-05-17 | $26.88M derived: sum of 3 quarters · filed 2021-05-17 | $46.05M derived: sum of 4 quarters · filed 2021-05-17 | |||
| 2019-12-31 | $9.15M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $17.32M derived: sum of 2 quarters · filed 2021-03-12 | $36.49M derived: sum of 3 quarters · filed 2021-03-12 | $32.38M 10-K · filed 2021-03-12 | $85.46M 10-K · filed 2020-03-12 | |||
| 2019-09-30 | $8.18M 10-Q · filed 2020-11-05 | $25.16M 10-Q · filed 2019-11-05 | $27.35M derived: sum of 2 quarters · filed 2020-11-05 | $23.24M 10-Q · filed 2020-11-05 | $56.02M 10-Q · filed 2019-11-05 | $28.84M derived: sum of 4 quarters · filed 2021-03-12 | ||
| 2019-06-30 | $19.17M 10-Q · filed 2020-07-30 | $30.86M 10-Q · filed 2020-07-30 | $20.66M derived: sum of 3 quarters · filed 2021-03-12 | $29.69M derived: sum of 4 quarters · filed 2021-03-12 | ||||
| 2019-03-31 | $11.69M 10-Q · filed 2020-05-07 | $1.49M derived: sum of 2 quarters · filed 2021-03-12 | $10.52M derived: sum of 3 quarters · filed 2021-03-12 | $24.64M derived: sum of 4 quarters · filed 2021-03-12 | ||||
| 2018-12-31 | -$10.20M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | -$1.17M derived: sum of 2 quarters · filed 2021-03-12 | $12.95M derived: sum of 3 quarters · filed 2021-03-12 | $23.14M 10-K · filed 2021-03-12 | $39.70M 10-K · filed 2019-03-18 | |||
| 2018-09-30 | $9.03M 10-Q · filed 2019-11-05 | $23.14M derived: sum of 2 quarters · filed 2019-11-05 | $33.34M 10-Q · filed 2019-11-05 | |||||
| 2018-06-30 | $14.11M 10-Q · filed 2019-08-14 | $24.31M 10-Q · filed 2019-08-14 | ||||||
| 2018-03-31 | $10.20M 10-Q · filed 2019-05-15 | |||||||
| 2017-12-31 | $18.88M 10-K · filed 2020-03-12 | |||||||
| 2016-12-31 | $1.00K 10-K · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |